肝脏 ›› 2025, Vol. 30 ›› Issue (1): 16-20.

• 药物性肝损伤 • 上一篇    下一篇

360例病理诊断的药物性肝损伤患者临床特征及预后分析

许姗姗, 仇丽霞, 柳雅立, 张晶   

  1. 100069 北京 首都医科大学附属北京佑安医院肝病中心三科;北京市医院管理局科研培育计划项目(PX202405 9)
  • 收稿日期:2024-06-10 出版日期:2025-01-31 发布日期:2025-03-10
  • 通讯作者: 张晶,Email:drzhangjing@163.com
  • 基金资助:
    2022年度院内中青年人才孵育项目(BJYAYY-YN2022-02)

The clinical features and prognosis of 360 patients with pathologically diagnosed drug-induced liver injury

XU Shan-shan, QIU Li-xia, LIU Ya-li, ZHANG Jing   

  1. Third Department of Liver Disease Center, Beijing YouAn Hospital, Capital Medical University,Beijing 100069, China
  • Received:2024-06-10 Online:2025-01-31 Published:2025-03-10
  • Contact: ZHANG Jing,Email: drzhangjing@163.com

摘要: 目的 探讨药物性肝损伤(drug-induced liver injury, DILI)患者的临床特点和预后影响因素。 方法 纳入2013年3月至2024年1月首都医科大学附属北京佑安医院诊断为DILI的患者360例。收集患者社会人口学资料、临床资料和转归情况,将患者分为好转组、恶化组,比较两组患者社会人口学资料和临床特征,应用单因素和多因素分析DILI预后的危险因素,并比较具有不同危险因素患者的恶化率。 结果 360患者的临床表现无特异性,年龄49.00(37.00, 57.00)岁,以女性(240例、66.70%)为主。可疑用药中,单一用药患者居多(314例、87.22%),且中药/中成药占比最高(53.90%)。好转组患者347例、恶化组患者13例。恶化组WBC、ALT、AST、TBil显著升高,CHE、Alb、PTA、Delta-TBil显著下降,且住院天数短。单因素分析和多因素分析发现,PTA(OR=0.716,95%CI:0.535~0.960,P=0.025)、Delta-TBil(OR=0.970,95%CI:0.941~0.999,P=0.044)是DILI预后的独立危险因素。将PTA、Delta-TBil进行分类变量处理,发现具有2个危险因素(PTA≤51和Delta-TBil≤-37.8)患者恶化率为100.00%,明显高于≥1个危险因素(PTA≤51或/和Delta-TBil≤-37.8)患者、无危险因素患者。 结论 PTA、Delta-TBil是影响DILI预后的危险因素,应对具有2个危险因素患者加强疾病监测,尽早行肝移植,减少死亡风险。

关键词: 药物性肝损伤, 临床特征, 预后, 危险因素

Abstract: Objective To investigate the clinical characteristics and prognostic factors of patients with drug-induced liver injury (DILI), so as to provide early warning for patients with high risk of DILI deterioration and reduce the risk of death. Methods Patients diagnosed with DILI by liver biopsy who were hospitalized to Beijing You An Hospital at Capital Medical University between March 2013 and January 2024 were collected. The social demographic information, clinical data, and patient outcomes were recorded and the patients were split into two groups: an improvement group and a deterioration group. Comparisons were made then between the social demographic information and clinical features of the two groups. The risk factors associated with DILI prognosis were analyzed by univariate and multifactorial analysis, and the rate of deterioration in patients with different risk factors was compared. Methods A total of 360 patients with a median age of 49.00 (37.00, 57.00) years were enrolled in this study, the clinical manifestations of enrolled patients were non-specific. Most of the patients were females (240 cases, 66.70%). Among the suspicious drugs used, the majority of patients were single drug use (314 cases, 87.22%), and the proportion of traditional Chinese medicine/proprietary Chinese medicine was the highest (53.90%). In this study, there were 347 patients in the improvement group and 13 patients in the deterioration group. When compared with the improvement group, the white blood cell count (WBC), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBil) in the deterioration group were significantly increased, cholinesterase (CHE), albumin (ALB), prothrombin time activity (PTA) and Delta-TBil were significantly decreased, and the number of hospital days was shorter. Univariate analysis and multivariate analysis showed that PTA (OR 0.716 (0.535,0.960), P=0.025) and Delta-TBil (OR 0.970 (0.941,0.999), P=0.044) were independent risk factors for the prognosis of DILI. PTA and Delta-TBil were processed as categorical variables. It was found that the deterioration rate of 100.00% in patients with 2 risk factors (PTA≤51 and Delta-TBil≤-37.8) was significantly higher than that in patients with ≥1 risk factor (PTA≤51 or/and Delta-TBil≤-37.8) and patients without risk factors. Conclusion The risk variables influencing DILI prognosis are PTA and Delta-TBil. To lower the mortality, patients with these two risk factors should have their disease surveillance reinforced and be placed in the liver transplant waiting list as soon as possible.

Key words: drug-induced liver injury, clinical features, prognosis, risk factor